From: Barriers to the conduct of randomised clinical trials within all disease areas
Duley and co-workers’ five major barriers to RCTs [5] | Comments | ECRIN’s eight major barriers to RCTs | Comments |
---|---|---|---|
Inadequate funding | Still highly relevant, but if a very substantial proportion of clinical research is considered wasted, it might not be the most prominent problem | Inadequate identification of the clinical research questions | Can only be based on systematic reviews of the literature. Added as a new barrier |
Overly complex regulations producing needlessly complex trial procedures | Still highly relevant | Inadequate knowledge and understanding of clinical research | Too often results from observational studies are used as evidence for interventions where randomised clinical trials ought to have been conducted |
Excessive monitoring | Still highly relevant | Inadequate knowledge and understanding of clinical trials | Too often when the randomised clinical trial design is chosen, it is not properly designed and conducted |
Over-restrictive interpretation of privacy laws without evidence of subject benefit | Still highly relevant | Inadequate funding | Funding could be used more effectively by teaching investigators how to properly use the clinical research designs available |
Inadequate understanding of methodology | Still highly relevant - the major problems have now been highlighted and brought to the forefront | Inadequate infrastructures | Added as a new barrier |
 |  | Overly complex regulation | There is a need to harmonise regulations of clinical trials on all interventions globally |
 |  | Excessive, non-focused monitoring | Should be assisted more through central monitoring in the future |
 |  | Too restrictive privacy and lack of transparency | Still highly relevant Lack of transparency added as new barrier |